SIBN · SI-BONE, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 3, 2026TL;DR. SI-BONE delivered ~15% Q2 revenue growth and a 178% adjusted EBITDA improvement while raising the low end of 2026 revenue guidance to $231–$233M and lowering the operating expense growth assumption to ~12%. The company filed a 510(k) for a third breakthrough product targeting complex spine procedures and highlighted finalized CMS reimbursement tailwinds, including new MS-DRGs for Granite effective October 1.
- + Q2 adjusted EBITDA improved 178% to $2.8M with revenue growing ~2x operating expenses.
- + Submitted 510(k) for a third breakthrough device targeting complex spine procedures, with phased launch planned for Q4 2026.
- + CMS finalized new MS-DRGs for complex spinal fusion incorporating Granite, with potential hospital payment increase up to $50,000 per procedure, effective October 1.
- − Guidance raise reflects measured approach; management is not assuming material Q4 contribution from the new product launch or reimbursement tailwinds.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIBN
this stock
SI-BONE, Inc.
|
$823.77M | -6.8% | +21.5% | — | 12.6% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIBN | -1.4% | -3.0% | +43.7% | -3.4% | -6.8% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -0.2% | -1.3% | +25.9% | -3.0% | -18.9% |